Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
Schaeffer Center experts propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation.
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development investment in Alzheimer’s disease, only five novel drugs have reached FDA approval.
Targeted therapies used in advanced-stage cancers improved mortality, whereas patients with early-stage cancers had little improvement in mortality from targeted drugs.
Healthcare Markets Researchers
Nonresident Senior Fellow, USC Schaeffer Center
Former Assistant, U.S. President
Former Director, Domestic Policy Council (DPC)
Director, Research, USC Schaeffer Center
Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, USC School of Pharmacy
Professor, USC Price School of Public Policy
Schaeffer Center Nonresident Senior Fellow and Former Director of the Domestic Policy Council Joe Grogan and AEI Senior Fellow and Former FDA Commissioner Scott Gottlieb joined Schaeffer Center Co-Director Erin Trish to discuss the challenges and opportunities facing the FDA and CMS in an age of breakthrough medical devices.Read Full Story
The medical need is too great that the FDA should not limit targeted therapies and diagnostics.
Medicare Coverage of Innovative Technologies: The U.S. Should do More to Speed Entry of Breakthrough Devices to Market
Schaeffer Center Expert Joe Grogan provides background on the proposed rule – Medicare Coverage of Innovative Technologies (MCIT) – and argues eliminating MCIT would abandon attempts to jumpstart American medical device innovation while also denying patients quick access to technologies that can improve their lives and their health.
Well-intended proposals to have the government intervene and “incentivize” biosimilar uptake may result in less price competition, not more.
It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
Learn more about HMI, including opportunities to collaborate